Author/Authors :
Nguyen, Vuong Thi Department of Oncology - Hanoi Medical University - Hanoi, Vietnam , Nguyen, Hieu Van Department of Oncology - Hanoi Medical University - Hanoi, Vietnam , Nguyen, Hung Van Department of Oncology - Hanoi Medical University - Hanoi, Vietnam , Nguyen, Long Thanh Department of Oncology - Hanoi Medical University - Hanoi, Vietnam , Pham, Nga Quynh Department of Oncology - Hanoi Medical University - Hanoi, Vietnam , Nguyen, Hau Xuan Department of Oncology - Hanoi Medical University - Hanoi, Vietnam , Nguyen, Hien Xuan Department of Oncology - Hanoi Medical University - Hanoi, Vietnam
Abstract :
In advanced gastric cancer, preoperative chemotherapy is associated with survival benefit. FOLFIRI has demonstratedpromising results in terms of survival and tolerance, especially in patients with poor performance status.Case Presentation. A 59-year-old male, diagnosed with pT4bN2M0 gastric cancer, underwent gastrointestinal anastomosis and three cycles of EOXchemotherapy. Due to disease progression, he was switched to FOLFIRI regimen. After 12 cycles, the patient received a subtotalgastrectomy and D2 lymphadenectomy. Microscopic examination achieved pCR, and the patient has been surviving 34 monthswithout recurrence. No severe toxicities of chemotherapy were recorded.Conclusions. FOLFIRI might be a safe and effectiveoption in neoadjuvant treatment for advanced gastric cancer among patients with poor performance status or progression afterfirst-line chemotherapy
Keywords :
Advanced Gastric Cancer , Folfiri , Preoperative Chemotherapy , FOLFIRI
